OVERSEA CHINESE BANKING Corp Ltd Has $35.64 Million Stock Holdings in Waters Corporation $WAT

Key Points

• OVERSEA CHINESE BANKING Corp Ltd increased its Waters position by 18.4% in the second quarter, purchasing 14,754 additional shares. Its 95,028 shares were worth approximately $35.64 million and represented 0.8% of its portfolio.
• Waters exceeded quarterly expectations, reporting $3.05 in adjusted EPS versus $3.01 expected and $1.65 billion in revenue versus $1.62 billion forecast. Revenue grew 113.3% year over year, and the company issued fiscal 2026 EPS guidance of $14.45 to $14.65.
• Analyst sentiment remains positive but mixed, with a “Moderate Buy” consensus and an average price target of $420.35. Institutional investors own 94.01% of Waters, while a company director recently sold 3,626 shares at an average price of $397.94.

OVERSEA CHINESE BANKING Corp Ltd increased its position in Waters Corporation (NYSE:WAT - Free Report) by 18.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 95,028 shares of the medical instruments supplier's stock after purchasing an additional 14,754 shares during the quarter. Waters makes up 0.8% of OVERSEA CHINESE BANKING Corp Ltd's holdings, making the stock its 22nd largest position. OVERSEA CHINESE BANKING Corp Ltd owned about 0.10% of Waters worth $35,639,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new position in Waters during the second quarter worth about $3,182,191,000. Janus Henderson Group PLC raised its stake in Waters by 27.0% in the first quarter. Janus Henderson Group PLC now owns 1,638,772 shares of the medical instruments supplier's stock valued at $488,028,000 after buying an additional 348,379 shares during the period. Geode Capital Management LLC raised its stake in Waters by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,593,388 shares of the medical instruments supplier's stock valued at $602,921,000 after buying an additional 8,590 shares during the period. Invesco Ltd. lifted its position in shares of Waters by 32.3% in the third quarter. Invesco Ltd. now owns 1,472,419 shares of the medical instruments supplier's stock valued at $441,446,000 after buying an additional 359,596 shares during the last quarter. Finally, Veritas Asset Management LLP boosted its stake in shares of Waters by 112.3% during the 4th quarter. Veritas Asset Management LLP now owns 1,241,206 shares of the medical instruments supplier's stock worth $471,447,000 after acquiring an additional 656,436 shares during the period. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Waters

In other news, Director Christopher A. Kuebler sold 3,626 shares of Waters stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the completion of the sale, the director owned 17,808 shares of the company's stock, valued at approximately $7,086,515.52. This trade represents a 16.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.31% of the company's stock.

Waters Price Performance

Waters stock opened at $405.62 on Friday. The company has a market capitalization of $39.85 billion, a price-to-earnings ratio of 101.15, a PEG ratio of 2.42 and a beta of 1.19. The company has a current ratio of 1.86, a quick ratio of 1.29 and a debt-to-equity ratio of 0.32. Waters Corporation has a 12 month low of $282.77 and a 12 month high of $421.74. The stock's 50 day moving average is $380.64 and its 200-day moving average is $346.78.

Waters (NYSE:WAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, topping the consensus estimate of $3.01 by $0.04. The business had revenue of $1.65 billion during the quarter, compared to analysts' expectations of $1.62 billion. Waters had a return on equity of 11.27% and a net margin of 3.58%.The firm's revenue for the quarter was up 113.3% compared to the same quarter last year. During the same period last year, the firm posted $2.95 EPS. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Equities research analysts expect that Waters Corporation will post 14.57 EPS for the current year.

Analysts Set New Price Targets

WAT has been the topic of a number of recent analyst reports. Weiss Ratings lowered Waters from a "hold (c)" rating to a "hold (c-)" rating in a report on Wednesday, August 12th. UBS Group raised their price target on Waters from $330.00 to $375.00 and gave the company a "neutral" rating in a report on Wednesday, May 6th. Wolfe Research initiated coverage on shares of Waters in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $425.00 price objective for the company. Wells Fargo & Company upped their price objective on shares of Waters from $370.00 to $400.00 and gave the company an "equal weight" rating in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of Waters from a "buy" rating to a "hold" rating in a research report on Monday, July 20th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $420.35.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source